AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24239167 — intervention group
Group type: COMPARATOR
Intervention: Control (no balance training)
Number of subjects: 63
Study 23401397 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise-only (EXO; 12-weeks exercise without diet-restriction)
Number of subjects: 79
Study 23401397 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypocaloric diet (DIO; 8-weeks very low energy diet (VLED) + 4-weeks weight maintenance diet)
Number of subjects: 79
Study 23401397 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypocaloric diet and exercise (DEX; 8-weeks VLED + 4-weeks weight maintenance diet combined with exercise throughout the 12 weeks)
Number of subjects: 79
Study 21247533 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive cardiothoracic CT protocol
Number of subjects: 59
Study 21247533 — intervention group
Group type: COMPARATOR
Intervention: Dedicated CT protocol
Number of subjects: 59
Study 19807791 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet supplemented with mixed nuts
Number of subjects: 238
Study 19807791 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet with virgin olive oil
Number of subjects: 238
Study 19807791 — intervention group
Group type: COMPARATOR
Intervention: Recommended low‐fat diet (control diet group)
Number of subjects: 238
Study 18001407 — intervention group
Group type: COMPARATOR
Intervention: omeprazole 20 mg b.i.d. + clarithromycin 500 mg b.i.d. + amoxicillin 1 g b.i.d. for 1 week
Number of subjects: 576
Study 18001407 — intervention group
Group type: EXPERIMENTAL
Intervention: pantoprazole 40 mg b.i.d. + clarithromycin 500 mg b.i.d. + amoxicillin 1 g b.i.d. for 1 week
Number of subjects: 576
Study 18001407 — intervention group
Group type: EXPERIMENTAL
Intervention: rabeprazole 20 mg b.i.d. + clarithromycin 500 mg b.i.d. + amoxicillin 1 g b.i.d. for 1 week
Number of subjects: 576
Study 18001407 — intervention group
Group type: EXPERIMENTAL
Intervention: esomeprazole 40 mg b.i.d. + clarithromycin 500 mg b.i.d. + amoxicillin 1 g b.i.d. for 1 week
Number of subjects: 576
Study 15143718 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination treatment with Chaihu Droplet pill (CHDP) and Huoxiang Zhengqi Droplet pill (HZDP) for 13 days
Number of subjects: 22
Study 15143718 — intervention group
Group type: COMPARATOR
Intervention: Symptomatic treatment only (Control)
Number of subjects: 22
Study 11448297 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual cognitive behavioral therapy
Number of subjects: 14
Study 11448297 — intervention group
Group type: EXPERIMENTAL
Intervention: Group psychotherapy
Number of subjects: 14
Study 11448297 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline therapy
Number of subjects: 14
Study 11448297 — intervention group
Group type: COMPARATOR
Intervention: Control group (nondepressed healthy subjects)
Number of subjects: 14
Study 9881239 — intervention group
Group type: EXPERIMENTAL
Intervention: Human insulin (group B, n = 46)
Number of subjects: 94
Study 9881239 — intervention group
Group type: COMPARATOR
Intervention: Animal insulin (group A, n = 48)
Number of subjects: 94
Study 7674870 — intervention group
Group type: EXPERIMENTAL
Intervention: Choline bitartrate (2.43 g)
Number of subjects: 20
Study 7674870 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 2282973 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 g ampicillin plus 1 g sulbactam, given intravenously every 6 h
Number of subjects: 54
Study 2282973 — intervention group
Group type: COMPARATOR
Intervention: 2 g cefoxitin, given intravenously every 6 h
Number of subjects: 54
Study 6111570 — intervention group
Group type: EXPERIMENTAL
Intervention: Codeine
Number of subjects: 247
Study 6111570 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentazocine
Number of subjects: 247
Study 6111570 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenteral morphine
Number of subjects: 247
Study 6111570 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone compound (equivalent to 12.5 mg morphine)
Number of subjects: 247
Study 6111570 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 247
Study 31654725 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Activity (PA) intervention conducted between November 2014 and June 2015
Number of subjects: 1129
Study 31654725 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Activity (PA) intervention
Number of subjects: 1129
Study 31654725 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 1129
Study 30840084 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive Affect (PA) intervention
Number of subjects: 120
Study 30840084 — intervention group
Group type: COMPARATOR
Intervention: Education (EDU)
Number of subjects: 120
Study 28701228 — intervention group
Group type: EXPERIMENTAL
Intervention: Single application of 4% chlorhexidine (CHX) at birth
Number of subjects: 4760
Study 28701228 — intervention group
Group type: COMPARATOR
Intervention: Dry cord care
Number of subjects: 4760
Study 25433727 — intervention group
Group type: EXPERIMENTAL
Intervention: Hands-on gel phantom training
Number of subjects: 50
Study 25433727 — intervention group
Group type: EXPERIMENTAL
Intervention: Instructional video training
Number of subjects: 50
Study 25433727 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 50
Study 23650124 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical capsaicin 8% (Qutenza)
Number of subjects: 1248
Study 23650124 — intervention group
Group type: COMPARATOR
Intervention: Topical low-dose capsaicin 0.04% (active control)
Number of subjects: 1248
Study 21247484 — intervention group
Group type: EXPERIMENTAL
Intervention: AMA1‐C1/Alhydrogel
Number of subjects: 300
Study 21247484 — intervention group
Group type: COMPARATOR
Intervention: Hiberix
Number of subjects: 300
Study 19589145 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient Advocate Crisis Plan (PACP)
Number of subjects: 0
Study 19589145 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinician facilitated Crisis Plan (CCP)
Number of subjects: 0
Study 19589145 — intervention group
Group type: COMPARATOR
Intervention: Control group (no psychiatric advance statement)
Number of subjects: 0
Study 17717313 — intervention group
Group type: EXPERIMENTAL
Intervention: OCSP diagnosis of lacunar stroke within 6 hours of onset
Number of subjects: 1367
Study 17717313 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients classified as OCSP 'LACS' within 6 hours
Number of subjects: 1367
Study 15464767 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual misoprostol (200 microg/tablet, 2 tablets)
Number of subjects: 120
Study 15464767 — intervention group
Group type: COMPARATOR
Intervention: Intravenous methylergometrine (200 microg, 1 ml)
Number of subjects: 120
Study 11209832 — intervention group
Group type: EXPERIMENTAL
Intervention: Participatory ergonomics program
Number of subjects: 0
Study 9609606 — intervention group
Group type: EXPERIMENTAL
Intervention: Provocation with perfume for 5 minutes (nose clip on)
Number of subjects: 10
Study 9609606 — intervention group
Group type: EXPERIMENTAL
Intervention: Provocation with perfume for 30 minutes (nose clip on)
Number of subjects: 10
Study 9609606 — intervention group
Group type: EXPERIMENTAL
Intervention: Provocation with perfume for 5 minutes (no nose clip)
Number of subjects: 10
Study 9609606 — intervention group
Group type: COMPARATOR
Intervention: Provocation with saline (placebo)
Number of subjects: 10
Study 7820061 — intervention group
Group type: EXPERIMENTAL
Intervention: Splenectomy after complete response (CR) to alpha interferon (IFN) therapy
Number of subjects: 169
Study 7820061 — intervention group
Group type: COMPARATOR
Intervention: Maintenance therapy
Number of subjects: 169
Study 7820061 — intervention group
Group type: COMPARATOR
Intervention: Alpha interferon (IFN) therapy
Number of subjects: 169
Study 7820061 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival rate
Number of subjects: 169
Study 2040042 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril 20 mg qd
Number of subjects: 160
Study 2040042 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study 7402084 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethinyl oestradiol 50 micrograms/day + norgestrel 250 micrograms/day
Number of subjects: 49
Study 7402084 — intervention group
Group type: EXPERIMENTAL
Intervention: Nordiol (combination of ethinyl oestradiol and norgestrel)
Number of subjects: 49
Study 7402084 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study 7402084 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatments
Number of subjects: 49
Study 31583253 — intervention group
Group type: EXPERIMENTAL
Intervention: Trigonella foenum‐graecum seed powder solution (25g orally twice a day for one month)
Number of subjects: 114
Study 31583253 — intervention group
Group type: COMPARATOR
Intervention: Metformin (control group)
Number of subjects: 114
Study 28756607 — intervention group
Group type: EXPERIMENTAL
Intervention: Dralitem® (200 mg/m2)
Number of subjects: 16
Study 28756607 — intervention group
Group type: COMPARATOR
Intervention: Temodal® (200 mg/m2)
Number of subjects: 16
Study 26449997 — intervention group
Group type: EXPERIMENTAL
Intervention: KIM-1 levels measured at baseline
Number of subjects: 874
Study 26449997 — intervention group
Group type: EXPERIMENTAL
Intervention: KIM-1 levels measured at 48-72 hours
Number of subjects: 874
Study 26449997 — intervention group
Group type: EXPERIMENTAL
Intervention: KIM-1 levels measured at 30 days
Number of subjects: 874
Study 24456668 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief online intervention comprising assessment, normative feedback, and advice on reducing drinking.
Number of subjects: 55000
Study 24456668 — intervention group
Group type: COMPARATOR
Intervention: Delayed access to online intervention (Control group).
Number of subjects: 55000
Study 21402611 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunophenotypic response (IR)
Number of subjects: 102
Study 21402611 — intervention group
Group type: COMPARATOR
Intervention: Complete response (CR)
Number of subjects: 102
Study 21402611 — intervention group
Group type: COMPARATOR
Intervention: Stringent complete response (stringent CR)
Number of subjects: 102
Study 19672655 — intervention group
Group type: EXPERIMENTAL
Intervention: AVAPS ventilation
Number of subjects: 9
Study 19672655 — intervention group
Group type: COMPARATOR
Intervention: PS ventilation
Number of subjects: 9
Study 19672655 — intervention group
Group type: EXPERIMENTAL
Intervention: AVAPS and PS ventilation
Number of subjects: 9
Study 17318558 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupressure therapy
Number of subjects: 0
Study 17318558 — intervention group
Group type: COMPARATOR
Intervention: Vitamin B6
Number of subjects: 0
Study 15042607 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening (serum PSA measurement and digital rectal examination)
Number of subjects: 46486
Study 15042607 — intervention group
Group type: COMPARATOR
Intervention: No screening (unscreened controls)
Number of subjects: 46486
Study 11303306 — intervention group
Group type: EXPERIMENTAL
Intervention: Hispanics and African Americans in the prospective cohort
Number of subjects: 161
Study 11303306 — intervention group
Group type: COMPARATOR
Intervention: Whites
Number of subjects: 161
Study 11303306 — intervention group
Group type: EXPERIMENTAL
Intervention: Larger combined prospective and retrospective groups of SSc patients
Number of subjects: 161
Study 11303306 — intervention group
Group type: EXPERIMENTAL
Intervention: HLA-DQB1*0301
Number of subjects: 161
Study 11303306 — intervention group
Group type: EXPERIMENTAL
Intervention: HLA-DRB1*11
Number of subjects: 161
Study 11303306 — intervention group
Group type: EXPERIMENTAL
Intervention: HLA-DRB1*01, DRB1*04, and DQB1*0501
Number of subjects: 161
Study 9931779 — intervention group
Group type: EXPERIMENTAL
Intervention: Local anesthesia
Number of subjects: 100
Study 9931779 — intervention group
Group type: COMPARATOR
Intervention: Open approach and transinguinal procedure
Number of subjects: 100
Study 8140488 — intervention group
Group type: EXPERIMENTAL
Intervention: Single 1 g dose of azithromycin
Number of subjects: 183
Study 8140488 — intervention group
Group type: COMPARATOR
Intervention: 100 mg doxycycline twice daily for seven days
Number of subjects: 183
Study 3073880 — intervention group
Group type: EXPERIMENTAL
Intervention: L-thyroxine treatment
Number of subjects: 20
Study 3073880 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 30309406 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.9% NaCl solution
Number of subjects: 280
Study 30309406 — intervention group
Group type: COMPARATOR
Intervention: Ringer solution
Number of subjects: 280
Study 30309406 — intervention group
Group type: COMPARATOR
Intervention: ASPMCG solution
Number of subjects: 280
Study 27581533 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg telmisartan/5 mg amlodipine/12.5 mg hydrochlorothiazide (T80/A5/H12.5)
Number of subjects: 132
Study 27581533 — intervention group
Group type: COMPARATOR
Intervention: 80 mg telmisartan/12.5 mg hydrochlorothiazide (T80/H12.5)
Number of subjects: 132
Study 26130347 — intervention group
Group type: EXPERIMENTAL
Intervention: TGF-ß1-expressing chondrocytes
Number of subjects: 54
Study 26130347 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 23599318 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic fundoplication
Number of subjects: 810
Study 23599318 — intervention group
Group type: COMPARATOR
Intervention: Medical management
Number of subjects: 810
Study 23599318 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery (fundoplication)
Number of subjects: 810
Study 21263351 — intervention group
Group type: EXPERIMENTAL
Intervention: Water Works Douching Device
Number of subjects: 140
Study 21263351 — intervention group
Group type: COMPARATOR
Intervention: Control group (over-the-counter plastic douching device)
Number of subjects: 140
Study 18958161 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-face recognition in children with ASD
Number of subjects: 0
Study 18958161 — intervention group
Group type: COMPARATOR
Intervention: Self-face recognition in typically developing (TD) children
Number of subjects: 0
Study 16698053 — intervention group
Group type: EXPERIMENTAL
Intervention: Antivenom A
Number of subjects: 67
Study 16698053 — intervention group
Group type: EXPERIMENTAL
Intervention: Antivenom B
Number of subjects: 67
Study 16698053 — intervention group
Group type: COMPARATOR
Intervention: Both antivenoms
Number of subjects: 67
Study 12743006 — intervention group
Group type: EXPERIMENTAL
Intervention: HCM patients with VF
Number of subjects: 266
Study 12743006 — intervention group
Group type: COMPARATOR
Intervention: HCM patients without VF
Number of subjects: 266
Study 12743006 — intervention group
Group type: EXPERIMENTAL
Intervention: DCM patients with VF
Number of subjects: 266
Study 12743006 — intervention group
Group type: COMPARATOR
Intervention: DCM patients without VF
Number of subjects: 266
Study 12743006 — intervention group
Group type: EXPERIMENTAL
Intervention: LQTS patients with VF
Number of subjects: 266
Study 12743006 — intervention group
Group type: COMPARATOR
Intervention: LQTS patients without VF
Number of subjects: 266
Study 12607205 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (40 mg/day) plus misoprostol (500 mg/day)
Number of subjects: 0
Study 12607205 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacine (100 mg/day) plus misoprostol (500 mg/day)
Number of subjects: 0
Study 12607205 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus misoprostol (500 mg/day)
Number of subjects: 0
Study 8835807 — intervention group
Group type: EXPERIMENTAL
Intervention: Bathing after admission assessment (M = 61.15 minutes of age)
Number of subjects: 100
Study 8835807 — intervention group
Group type: COMPARATOR
Intervention: Standard bathing at 4 hours of age (M = 252.12 minutes of age)
Number of subjects: 100
Study 1598427 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticlopidine (500 mg/day for 30 days)
Number of subjects: 43
Study 1598427 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (30 mg/day for 30 days)
Number of subjects: 43
Study 1598427 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study 1598427 — intervention group
Group type: COMPARATOR
Intervention: Control (healthy volunteers without treatment)
Number of subjects: 43
Study 6144128 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg zimelidine each morning for 5 days
Number of subjects: 10
Study 6144128 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg temazepam 2 h after zimelidine
Number of subjects: 10
Study 6144128 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 30102413 — intervention group
Group type: EXPERIMENTAL
Intervention: Selumetinib (75 mg twice daily) plus docetaxel
Number of subjects: 0
Study 30102413 — intervention group
Group type: EXPERIMENTAL
Intervention: Selumetinib (75 mg twice daily)
Number of subjects: 0
Study 29117073 — intervention group
Group type: EXPERIMENTAL
Intervention: Yerba Mate (YM)
Number of subjects: 11
Study 29117073 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 11
Study 26932437 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemoradiotherapy (CRT) using a moderate radiation dose weekly combined with carboplatin and paclitaxel followed by surgery
Number of subjects: 0
Study 26932437 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 0
Study 26932437 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemoradiotherapy (CRT)
Number of subjects: 0
Study 24841093 — intervention group
Group type: EXPERIMENTAL
Intervention: Incremental theory intervention
Number of subjects: 0
Study 24841093 — intervention group
Group type: COMPARATOR
Intervention: Entity theory (control)
Number of subjects: 0
Study 23223738 — intervention group
Group type: EXPERIMENTAL
Intervention: Auriculotherapy
Number of subjects: 71
Study 23223738 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71
Study 23223738 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 71
Study 20385970 — intervention group
Group type: EXPERIMENTAL
Intervention: Home BP
Number of subjects: 2081
Study 20385970 — intervention group
Group type: COMPARATOR
Intervention: Office BP
Number of subjects: 2081
Study 20385970 — intervention group
Group type: EXPERIMENTAL
Intervention: Systolic home BP
Number of subjects: 2081
Study 18032226 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritalin (methylphenidate)
Number of subjects: 0
Study 18032226 — intervention group
Group type: COMPARATOR
Intervention: Amphetamines
Number of subjects: 0
Study 18032226 — intervention group
Group type: COMPARATOR
Intervention: Cocaine
Number of subjects: 0
Study 15749500 — intervention group
Group type: EXPERIMENTAL
Intervention: Gynetics catheter
Number of subjects: 251
Study 15749500 — intervention group
Group type: COMPARATOR
Intervention: Makler cannula
Number of subjects: 251
Study 11865270 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycled light (CL) from birth
Number of subjects: 0
Study 11865270 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycled light (CL) at 32 weeks' PCA
Number of subjects: 0
Study 11865270 — intervention group
Group type: COMPARATOR
Intervention: Cycled light (CL) at 36 weeks' PCA
Number of subjects: 0
Study 11865270 — intervention group
Group type: COMPARATOR
Intervention: Near darkness (ND) until 36 weeks' PCA
Number of subjects: 0
Study 10468165 — intervention group
Group type: EXPERIMENTAL
Intervention: Nabumetone
Number of subjects: 394
Study 10468165 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac retard
Number of subjects: 394
Study 8574252 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethinyl estradiol 30 micrograms and gestodene 75 micrograms (oral contraceptives)
Number of subjects: 11
Study 8574252 — intervention group
Group type: COMPARATOR
Intervention: Control group (diabetic women not taking OCs)
Number of subjects: 11
Study 2150580 — intervention group
Group type: EXPERIMENTAL
Intervention: Nafarelin (400 micrograms/day intranasally)
Number of subjects: 18
Study 2150580 — intervention group
Group type: EXPERIMENTAL
Intervention: Danazol (600 mg/day orally)
Number of subjects: 18
Study 758493 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of dihydroergotamine and heparin
Number of subjects: 300
Study 758493 — intervention group
Group type: COMPARATOR
Intervention: Heparin calcium
Number of subjects: 300
Study 758493 — intervention group
Group type: COMPARATOR
Intervention: Dihydroergotamine mesylate
Number of subjects: 300
Study 31036625 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab 60 mg every 3 months (Q3M)
Number of subjects: 654
Study 31036625 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab 60 mg every 6 months (Q6M)
Number of subjects: 654
Study 31036625 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 654
Study 27402913 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-thioguanine nucleotide (6-TGN) concentrations at T1
Number of subjects: 194
Study 27402913 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-methylmercaptopurine ribonucleotide (6-MMPR) concentrations at T1
Number of subjects: 194
Study 27402913 — intervention group
Group type: COMPARATOR
Intervention: Mercaptopurine treatment
Number of subjects: 194
Study 27402913 — intervention group
Group type: COMPARATOR
Intervention: Concurrent anti-TNF therapy
Number of subjects: 194
Study 27402913 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevations of both T1 6-TGN and 6-MMPR
Number of subjects: 194
Study 27402913 — intervention group
Group type: EXPERIMENTAL
Intervention: Exceeding only the T1 6-MMPR or 6-TGN threshold concentration
Number of subjects: 194
Study 25129372 — intervention group
Group type: EXPERIMENTAL
Intervention: Caudal extension graft (CEG)
Number of subjects: 0
Study 25129372 — intervention group
Group type: COMPARATOR
Intervention: Columellar strut with plumping graft (CSPG)
Number of subjects: 0
Study 23410235 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnosis threat (DT) group (n=15)
Number of subjects: 45
Study 23410235 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced threat (DT-reduced) group (n=15)
Number of subjects: 45
Study 23410235 — intervention group
Group type: COMPARATOR
Intervention: Neutral group (n=15)
Number of subjects: 45
Study 21836105 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard care plus yoga for 3 months
Number of subjects: 123
Study 21836105 — intervention group
Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 123
Study 19492974 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivastigmine
Number of subjects: 0
Study 19492974 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil
Number of subjects: 0